Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

Revision of Results Forecast for the Fiscal Year Ending December 31, 2020

Financial Results FY2020Q3

Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2020

Carna announces the initiation of dosing in a First-in-Human Phase 1 study of AS-0871

Carna announces the initiation of dosing in a First-in-Human Phase 1 study of AS-0871.

Financial Results FY2020Q2

Consolidated Financial Results for the Second Quarter of the Year Ending December 31, 2020

Carna Biosciences Reacquires Worldwide Rights to Develop and Commercialize AS-0141